GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>By the 1st of the year… they will probably only have 38 million in cash, which will probably make further dilution a necessity by end of 2007, unless ATryn sells unexpectedly well.<

For 2007, what’s more important than the royalties from sales of ATryn in HD (which are apt to be small) is whether GTC can ink some Merrimack-like production deals that bring in up-front licensing fees and milestones. If they can, another financing transaction in 2007 may not be necessary.

>With all the new shares, I see GTCB having a PPS of around 84 cents…<

I’ll be astonished if the share price reaches a level that low. I’d say that has less than a 2% chance of happening.